We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit

by admin
januari 11, 2023

We are presenting our data at the DDR inhibitor summit, January 24 – 26, 2023, Boston, US
We are excited to hear about the newest progress in the DDR field and look forward to all interesting
discussions.

Rekommenderade artiklar

One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million)

Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage

One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors

Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics AB, a clinical-stage biotechnology

One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe

One-carbon therapeutics AB is discussing the ODIN trial with several